Bacterial community-acquired pneumonia: risk factors for mortality and supportive therapies

Lode, H.
March 2009
Intensive Care Medicine;Mar2009, Vol. 35 Issue 3, p391
Academic Journal
The article discusses various reports published within the issue, including one on bacterial community-acquired pneumonia (CAP) patients with antibiotic therapy, and another on survival benefits of CAP patients.


Related Articles

  • Penicillin Combats Resistance.  // Australasian Science;Oct2008, Vol. 29 Issue 9, p10 

    This article reports on a study on the use of penicillin to treat community-acquired pneumonia in order to slow the spread of resistant bacteria. Conducted by Patrick Charles of the University of Melbourne in Victoria, study examined the causes of disease in pneumonia patients admitted to...

  • Bacteremic Streptococcus pneumoniae in Community-Acquired Pneumonia: An Update. Herrero, Francisco Sanz; Pérez, Tomás Lloret; Olivas, José Blanquer // Current Respiratory Medicine Reviews;2010, Vol. 6 Issue 3, p188 

    Invasive pneumococcal disease is a major cause of morbimortality worldwide. The presence of bacteremia in pneumococcal pneumonia constitutes an additional factor of worse prognosis, although the highest virulence of invasive pneumococcal infection is clustered in certain serotypes. Antibiotic...

  • Detection of Legionella pneumophila serogroup 1 in blood cultures from a patient treated with tumor necrosis factor-alpha inhibitor. Kaku, Norihito; Yanagihara, Katsunori; Morinaga, Yoshitomo; Sato, Tsuyoshi; Nakashima, Munetoshi; Sakai, Takahiro; Tominaga, Hiroo; Wakigawa, Fumiko; Nagashima, Seiji; Fukuda, Minoru; Hashiguchi, Kohji; Kohno, Shigeru // Journal of Infection & Chemotherapy (Springer Science & Business;Feb2013, Vol. 19 Issue 1, p166 

    A 65-year-old man was admitted to our hospital with a temperature of 39.3 °C, cough, sputum, and pharyngeal discomfort that had persisted for 3 days. He had been treated with methotrexate and adalimumab (a tumor necrosis factor-alpha [TNF-α] inhibitor) for rheumatoid arthritis for 2 years,...

  • Unique Considerations in the Evaluation of Antibacterials in Clinical Trials for Pediatric Community-Acquired Pneumonia. Bradley, John S.; McCracken, George H. // Clinical Infectious Diseases;12/1/2008 Supplement 3, Vol. 47, pS241 

    There are few placebo-controlled, randomized, prospective clinical trials of antibiotic therapy for community- acquired pneumonia (CAP) in children. The reduction in mortality seen in early trials of antibacterials for treatment of bacterial CAP in adults and children was dramatic and led to the...

  • INFECTIONS & INFESTATIONS.  // Monthly Prescribing Reference;Sep2011, Vol. 27 Issue 9, p192 

    The article presents several drug prescriptions for the treatment of various infections and infestations. It says that amoxicillin capsules such as broad-spectrum penicillin are used to treat susceptible infections including ear/nose/throat (ENT). It tells that Augmentin XR from GlaxoSmithKline...

  • Atypical bacterial pathogens in community-acquired pneumonia in children: a hospital-based study. Agarwal, Jyotsna; Awasthi, Shally; Rajput, Anuradha; Tiwari, Manoj; Jain, Amita // Tropical Doctor;Apr2008, Vol. 39 Issue 2, p109 

    A total of 243 children aged one month to five years with World Health Organization defined severe community acquired pneumonia were studied for the presence of atypical bacterial pathogens: 24 were found positive for mycoplasma infection. There was no significant association with any of the...

  • H1N1 influenza pneumonia and bacterial coinfection. Calbo, Esther; Robles, Alejandro; Sangil, Anna; Benet, Susana; Viladot, Maria Eugenia; Pascual, Vanesa; Barreiro, Bienvenido // Thorax;Dec2011, Vol. 66 Issue 12, p1091 

    The model described by Bewick et al seems to be able to distinguish between H1N1 influenza-related pneumonia and non-H1N1 community acquired pneumonia (CAP) based on five criteria. However, bacterial infection in the influenza group has not been accurately excluded. Therefore, this model could...

  • Role of laboratory variables in differentiating SARS-coronavirus from other causes of community-acquired pneumonia within the first 72 h of hospitalization. Lee, N.; Rainer, T. H.; Ip, M.; Zee, B.; Ng, M. H.; Antonio, G. E.; Chan, E.; Lui, G.; Cockram, C. S.; Sung, J. J.; Hui, D. S. // European Journal of Clinical Microbiology & Infectious Diseases;Dec2006, Vol. 25 Issue 12, p765 

    The Centers for Disease Control and Prevention (CDC) recommend that SARS-coronavirus (SARS-CoV) testing be considered in epidemiologically high-risk patients hospitalized with community-acquired pneumonia (CAP) if no alternative diagnosis is identified after 72 h. The aim of this study was to...

  • Increasing Incidence of Empyema Complicating Childhood Community-Acquired Pneumonia in the United States. Grijalva, Carlos G.; Nuorti, J. Pekka; Yuwei Zhu; Griffin, Marie R. // Clinical Infectious Diseases;3/15/2010, Vol. 50 Issue 6, p805 

    Background. The incidence of childhood pneumonia decreased following introduction of 7-valent pneumococcal conjugate vaccine (PCV7) in the United States. Recent regional reports suggest an increase in the incidence of childhood pneumonia complicated by empyema. We assessed whether early...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics